Engineering an End to The Opioid Epidemic

Robert Brooke is the CEO and co-founder of Vitality Biopharma, a drug development company dedicated to unlocking the power of cannabinoids for treatment of serious neurological and inflammatory conditions. Previously, he was the founder of a cancer drug development company that is now known as Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Mr. Brooke is also a co-founder and serves on a limited part-time basis as the CEO of Intervene Immune, Inc. From 2004 to 2008, he was an analyst with Bristol Capital Advisors, LLC, investment manager to Bristol Investment Fund, Ltd. During this period, Bristol financed over 60 public healthcare and life science companies, and was listed by The PIPEs Report in 2005 as being the most active investor in private placements by public biotechnology companies. Mr. Brooke has a BS in electrical engineering from Georgia Tech and an MS in biomedical engineering from UCLA.